Mesa Laboratories Inc

Industrials
Industrial Machinery/Components
www.mesalabs.com

Earnings Score
Moat Score
Safety Score

Market Cap $670.22M
PE -3
Debt $170.15M
Cash $24.34M
EV $816.04M
FCF $35.78M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$245.65M
EBIT	-$262.26M
ROE	-152%
ROA	-58%
FCF	$35.78M
Equity	$161.45M
Growth Stability	-13K%
PE	-2.73
PEG	0.58
PB	4.15
P/FCF	18.73
P/S	2.93
Price/Cash	0.04
Debt/Equity	1.05
Debt/FCF	4.76
Net Margins	6%
Gross Margins	62%
Op. Margins	-115%
Earnings CAGR	-5%
Sales Growth YoY	9%
Sales Growth QoQ	-1%
Sales CAGR	14%
FCF CAGR	19%
Equity CAGR	20%
Earnings Stability	0.13
Earnings Growth YoY	-379%
Earnings Growth QoQ	1%
Earnings CAGR 5Y	-5%

Sales CAGR 5Y	18%
FCF CAGR 5Y	6%
Equity CAGR 5Y	-8%
Earnings CAGR 3Y	8%
Sales CAGR 3Y	8%
FCF CAGR 3Y	13%
Equity CAGR 3Y	-29%
Market Cap	$670.22M
Revenue	$228.38M
Dividend Yield	1%
Payout Ratio	-1%
Assets	$454.10M
Total Debt	$170.15M
Cash	$24.34M
Shares Outstanding	5.41M
EV	816.04M
Earnings Score	5%
Moat Score	28%
Safety Score	53%
Final Score	29%
Working Capital	-45.25M
Current Ratio	0.7
Gross Profit	$142.66M
Shares Growth 3y	1%
Equity Growth QoQ	7%
Equity Growth YoY	-58%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization & Disinfection Control, which manufactures and sells biological, cleaning, and chemical indicators. It also provides testing and laboratory services, mainly to the dental industry; Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions; Calibration Solutions division develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters for health and safety purposes; and Clinical Genomics. Its geographical segments include United States and Foreign.

SEC Filings

Direct access to Mesa Laboratories Inc (MLAB) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-K Mar 31

Sector Comparison

How does Mesa Laboratories Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Mesa Laboratories Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%

Stability 13%

loading chart...

Mesa Laboratories Inc Discounted Cash Flow

Fully customizable DCF calculator online for Mesa Laboratories Inc .

Years

Calculation mode

= $1.4B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$36M	$43M	$51M	$61M	$73M	$87M	$104M	$124M	$148M	$176M	$211M	$2.1B
DCF		$39M	$42M	$46M	$50M	$54M	$59M	$64M	$69M	$75M	$81M	$812M
Value	$1.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	03/2015	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Net Margins	13%	13%	12%	-3%	7%	1%	2%	1%	0%	-118%	6%
ROA	-	10%	9%	1%	7%	2%	2%	1%	1%	-61%	-58%
ROE	-	13%	11%	-3%	7%	1%	1%	0%	0%	-175%	-152%

Bad Net Margins (5.88%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	03/2015	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	TTM
Debt over FCF	-	5.26	-14.62	2.12K	0.86	5.6	4.15	4.87	7.26	4.12	4.76
Debt over Equity	0.4	0.57	0.58	469.26	0.23	0.64	0.36	0.43	0.43	1.18	1.05
Growth Stability	-	-	-	-28%	100%	26%	100%	46%	43%	-13K%	-13K%

Bad Debt/FCF ratio (4.76)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.05)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-13K%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	03/2015	03/2016	03/2017	03/2018	03/2019	03/2020	03/2021	03/2022	03/2023	03/2024	CAGR 5Y
Revenue YoY growth	-	19%	11%	3%	7%	14%	14%	38%	19%	-1%	18%
Earnings YoY growth	-	17%	0%	-126%	-353%	-82%	143%	-43%	-50%	-27K%	-5%
Equity YoY growth	-	15%	16%	2%	12%	98%	85%	-3%	-0%	-63%	-8%
FCF YoY growth	-	15%	-142%	-671%	33%	-14%	40%	-1%	-33%	77%	6%